Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ryan Haiar

Optometrist Sioux Falls, SD Doctor of Optometry

NPI 1689795494 CMS profile 349387

5129 S Western Ave, Sioux Falls, SD 57108

Open in the dashboard

General payments

$4,439

65 records reported · program years 2019–2025

Research payments

$109

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ryan Haiar of Sioux Falls, SD is reported in the CMS Open Payments database as having received $4,439 across 65 general payments and $109 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $269 7
2024 General $364 7
2023 General $2,106 11
2022 General $552 18
2022 Research $109 1
2021 General $535 8
2020 General $212 8
2019 General $401 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ryan Haiar
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Ryan Haiar were reported at $269. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Ryan Haiar Optometrist median Middle half National median
2019 $401 $159 $67–$371 $163
2020 $212 $72 $29–$165 $114
2021 $535 $125 $46–$292 $132
2022 $552 $162 $66–$374 $149
2023 $2,106 $177 $72–$406 $160
2024 $364 $188 $77–$427 $164
2025 $269 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alcon Vision LLC $2,489 14 payments
  2. Johnson & Johnson Vision Care, Inc. $814 27 payments
  3. Bausch & Lomb Americas Inc. $328 3 payments
  4. CooperVision Inc. $248 5 payments
  5. Bausch & Lomb, a division of Bausch Health US, LLC $156 4 payments
  6. AbbVie, Inc. $114 5 payments
  7. Glaukos Corporation $90 1 payment
  8. Alexion Pharmaceuticals, Inc. $85 1 payment
  9. Carl Zeiss Meditec AG $39 2 payments
  10. Tarsus Pharmaceuticals, Inc. $29 1 payment
  11. Other $45 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,766 59 payments
  2. Travel and Lodging $1,340 3 payments
  3. Consulting Fee $293 1 payment
  4. Gift $39 2 payments
Products named General payments · program years 2019–2025
  1. AIR OPTIX $1,784 4 payments
  2. Dailies Aqua Comfort Plus $1,286 2 payments
  3. Acuvue $743 24 payments
  4. DAILIES TOTAL1 Multifocal $443 1 payment
  5. INFUSE $328 3 payments
  6. Precision 1 $287 4 payments
  7. BIOTRUE $207 2 payments
  8. Multiple Brands Contact Lens $201 3 payments
  9. ULTRA $156 4 payments
  10. DAILIES $148 1 payment
  11. Other $937 24 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. AbbVie, Inc. $109 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

202

Median for Optometry: 120

Drug cost

$33,187

Median for Optometry: $8,864

Branded share of claims

37.1%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 26 $16,873
Lumigan Bimatoprost Brand 25 $14,007
Latanoprost Generic 88 $1,035
Tobramycin-Dexamethasone Tobramycin/Dexamethasone Brand 12 $550
Prednisolone Acetate Generic 12 $308
Timolol Maleate Generic 27 $212
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 12 $202

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$46,284

Medicare's payments for the services billed

Medicare patients

391

Average age 72

Services billed

685

228 women, 163 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 40%
Ischemic heart disease 24%
Diabetes 21%
Osteoporosis 19%
Depression 18%
Chronic kidney disease 17%
Atrial fibrillation 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

66 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in South Dakota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record